Suchergebnisse - "Amin, Asim"

PubPharm (100)

1

Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358) : a phase 1-2, open-label, multicohort trial

enthalten in: The Lancet. Oncology | 2024

von Oaknin, A. | Moore, K. | Meyer, T. | +17

2

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

enthalten in: Journal for immunotherapy of cancer | 2024

von Callahan, M. | Amin, A. | Kaye, F. | +9

3

Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2 : A Real-world Evidence Study of Patients with Advanced Renal Cancer

enthalten in: Cancer research communications | 2022

von Eisner, J. | Beebe, K. | Mayhew, G. | +11

4

Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy

enthalten in: Thrombosis research | 2021

von Hill, H. | Robinson, M. | Lu, L. | +4

5

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

enthalten in: Journal of investigative medicine : the official publication of the American Federation for Clinical Research | 2021

von Clark, J. | Curti, B. | Davis, E. | +11

6

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Topalian, S. | Bhatia, S. | Amin, A. | +21

7

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma : 42-month follow-up of a randomized phase 3 clinical trial

enthalten in: Journal for immunotherapy of cancer | 2020

von Motzer, R. | Escudier, B. | McDermott, D. | +26

ErratumIn: J Immunother Cancer. 2021 May;9(5):. - PMID 33941652

8

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer : Results From the CheckMate 032 Randomized Cohort

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Ready, N. | Ott, P. | Hellmann, M. | +17

CommentIn: J Thorac Oncol. 2020 Mar;15(3):308-310. - PMID 32093850

9

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases : A case series

enthalten in: Cancer | 2020

von Holbrook, K. | Lutzky, J. | Davies, M. | +7

10

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma : extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Motzer, R. | Rini, B. | McDermott, D. | +36

CommentIn: Lancet Oncol. 2019 Oct;20(10):1331-1332. - PMID 31427206

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]